T-cell costimulation in graftversus- host disease and graft-versus-leukemia effect - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 214

[47] Hubbard VM, Eng JM, Ramirez-Montagut T, Tjoe KH, Muriglan SJ, Kochman AA, et al.
Absence of inducible costimulator on alloreactive T cells reduces graft versus host
disease and induces Th2 deviation. Blood 2005;106:3285-92.
[48] Yu XZ, Liang Y, Nurieva RI, Guo F, Anasetti C, Dong C. Opposing effects of ICOS
on graft-versus-host disease mediated by CD4 and CD8 T cells. J Immunol
2006;176:7394-401.
[49] Suh WK, Tafuri A, Berg-Brown NN, Shahinian A, Plyte S, Duncan GS, et al. The inducible
costimulator plays the major costimulatory role in humoral immune responses in the
absence of CD28. J Immunol 2004;172:5917-23.
[50] Nanji SA, Hancock WW, Anderson CC, Adams AB, Luo B, Schur CD, et al. Multiple
combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate
long-term islet allograft survival. Am J Transplant 2004;4:526-36.
[51] Poirier N, Blancho G, Vanhove B. A more selective costimulatory blockade of the CD28-
B7 pathway. Transplant Int 2011;24:2-11.
[52] Tajima N, Tezuka K, Tanimoto A, Miyai A, Tanimoto M, Maruhashi J, et al. JTA-009, a
fully human antibody against human AILIM/ICOS, ameliorates graft-vs-host reaction
in SCID mice grafted with human PBMCs. Exp Hematol 2008;36:1514-23.
[53] Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity.
Immunol Rev 2010;236:219-42.
[54] Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of
programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine
production. J Immunol 2003;170:1257-66.
[55] Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoim-
mune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying
immunoreceptor. Immunity 1999;11:141-51.
[56] Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune
dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291:319-22.
[57] Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H, et al.
Blockade of programmed death-1 engagement accelerates graft-versus-host disease
lethality by an IFN-gamma-dependent mechanism. J Immunol 2003;171:1272-7.
[58] Habicht A, Kewalaramani R, Vu MD, Demirci G, Blazar BR, Sayegh MH, et al. Striking
dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+)
T cells in vivo. Am J Transplant 2007;7:2683-92.
[59] Li X, Deng R, He W, Liu C, Wang M, Young J, et al. Loss of B7-H1 expression by recipient
parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence
of graft-versus-host disease. J Immunol 2012;188:724-34.
[60] Asakura S, Hashimoto D, Takashima S, Sugiyama H, Maeda Y, Akashi K, et al. Alloan-
tigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in
mice. J Clin Invest 2010;120:2370-8.
[61] Koestner W, Hapke M, Herbst J, Klein C, Welte K, Fruehauf J, et al. PD-L1 blockade
effectively restores strong graft-versus-leukemia effects without graft-versus-host
disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic
CD8+ T cells. Blood 2011;117:1030-41.
[62] Murphy KM, Nelson CA, Sedy JR. Balancing co-stimulation and inhibition with BTLA
and HVEM. Nat Rev Immunol 2006;6:671-81.
[63] Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, et al. BTLA is a lymphocyte
inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003;4:670-9.
[64] Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ. CD160 inhibits
activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
Nat Immunol 2008;9:176-85.
[65] Hurchla MA, Sedy JR, Murphy KM. Unexpected role of B and T lymphocyte
attenuator in sustaining cell survival during chronic allostimulation. J Immunol
2007;178:6073-82.
[66] Albring JC, Sandau MM, Rapaport AS, Edelson BT, Satpathy A, Mashayekhi M, et al.
Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease
without global immunosuppression. J Exp Med 2010;207:2551-9.
[67] Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism
and function of CD40/CD40L engagement in the immune system. Immunol Rev
2009;229:152-72.
[68] Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4(+) T cells tolerized ex vivo to host
alloantigen by anti-CD40 ligand (CD40L: CD154) antibody lose their graft-versus-
host disease lethality capacity but retain nominal antigen responses. J Clin Invest
1998;102:473-82.
[69] Taylor PA, Friedman TM, Korngold R, Noelle RJ, Blazar BR. Tolerance induction of allo-
reactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results
in the generation of a potent immune regulatory cell. Blood 2002;99:4601-9.

217